NDASUBLINGUALTABLET
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) by Bridge Therapeutics is naloxone. First approved in 2013.
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUBSOLV is a sublingual tablet combining buprenorphine (partial mu-opioid agonist) and naloxone (opioid antagonist) for opioid use disorder treatment. Buprenorphine provides sustained opioid activity while naloxone deters misuse via injection by precipitating withdrawal. The combination reduces illicit use risk and supports medication-assisted treatment compliance.
$28.0MPart D
Peak5.9 years to LOEAt peak lifecycle with steady Part D utilization (~52K claims annually), indicating stable commercial team size and mature market operations.
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
Started Nov 2013
33 enrolled
Opioid Dependence
Career Relevance
ZUBSOLV offers career opportunities primarily in commercial, medical affairs, and managed care roles rather than R&D, as the product is mature with no active pipeline. Working on this asset provides deep expertise in specialty pharma, addiction medicine, and payer dynamics, with stability through peak lifecycle but urgency around pre-LOE strategy execution.
Brand Manager
Worked on ZUBSOLV at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.